SEC Filings

S-1/A
AVEXIS, INC. filed this Form S-1/A on 02/09/2016
Entire Document
 

Table of Contents

development expense of $9.5 million in the quarter ended March 31, 2016 related to this acceleration. We are in the process of finalizing our financial statements for the year ended December 31, 2015 and have not yet determined the fair value of our common stock as of December 31, 2015. As a result, actual results could differ materially from this estimate.

          In addition, under the restricted stock purchase agreement, or RSPA, we are obligated to indemnify Dr. Brian Kaspar against certain adverse tax events with respect to the shares of our common stock he purchased under the agreement, and such obligation survived the termination of the RSPA effective January 1, 2016. Dr. Brian Kaspar purchased the shares at a price of $0.00007 per share, which was the par value of the shares. Based on our estimate of the fair market value per share of our common stock as of the date of the RSPA of $1.51 per share, Dr. Brian Kaspar purchased these shares at a discount of $1.5144 per share. Therefore, we estimate that we are contractually obligated to indemnify Dr. Brian Kaspar for the tax he owes on the imputed income of $3.5 million, based on the difference between the fair market value of the restricted share grant and the purchase price paid. We estimate our total indemnity obligation will be approximately $4.1 million, including gross-up, interest and penalties. As a result, we have accrued $4.1 million at December 31, 2014, representing our best estimate of the ultimate tax indemnification. Such amount has been recorded as research and development expense in our consolidated statements of operations for the year ended December 31, 2014.

          The table below summarizes the stock-based compensation expense recognized in our statements of operations by type:

 
  Year Ended
December 31,
  Nine Months Ended
September 30,
 
 
 
2013
 
2014
 
2014
 
2015
 

Stock sales to former chief executive officer

  $ 1,227,744   $ 594,088   $ 594,088   $  

Share exchange with former chief executive officer

        193,549     193,549      

Restricted stock grant to consultant

        5,749,791     2,886,762     14,464,714  

Warrants issued to consultant

        243,863     98,490     358,637  

Employee stock-option grants

        416,624     369,180     2,719,702  

  $ 1,227,744   $ 7,197,915   $ 4,142,069   $ 17,543,053  

          The table below summarizes the stock-based compensation expense recognized in our statements of operation by classification:

 
  Year Ended
December 31,
  Nine Months Ended
September 30,
 
 
 
2013
 
2014
 
2014
 
2015
 

Research and development

  $   $ 6,173,295   $ 3,136,359   $ 15,234,608  

General and administrative

    1,227,744     1,024,620     1,005,710     2,308,445  

  $ 1,227,744   $ 7,197,915   $ 4,142,069   $ 17,543,053  

Determination of the Fair Value of Stock-Based Compensation Grants

          The following table summarizes by grant date the number of shares of our common stock subject to stock option and stock warrants granted during 2014 and 2015, as well as the

91



© AveXis, Inc. All Rights Reserved.